Shopping Cart
- Remove All
- Your shopping cart is currently empty
Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug under development for treating acute bacterial skin and skin structure infections, as well as community-acquired pneumonia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $954 | 8-10 weeks | |
50 mg | $1,240 | 8-10 weeks | |
100 mg | $1,990 | 8-10 weeks |
Description | Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug under development for treating acute bacterial skin and skin structure infections, as well as community-acquired pneumonia. |
In vitro | Avarofloxacin demonstrates an antibacterial effect against numerous Gram-positive bacteria (mean MIC90: 0.12 mg/L) [2]. Avarofloxacin has the potential for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections [3]. |
Alias | JNJ-Q2 |
Molecular Weight | 419.42 |
Formula | C21H23F2N3O4 |
Cas No. | 878592-87-1 |
Relative Density. | 1.450 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.